Description
📌 Source: gpt-image2.art · Creator: gpt-image2.art
Real People
PD-1/PD-L1 Immune Checkpoint Pathway
✦ Prompt
High-quality scientific schematic diagram in Science/Nature journal style. Topic: PD-1/PD-L1 immune checkpoint pathway in the tumor microenvironment. Light gray-white background. Left side: a simplified T-cell cross-section, cell membrane drawn as a phospholipid bilayer (light blue), with PD-1 receptor protein (purple) protruding from the membrane; PD-1 intracellular tail connects via ITSM motif to downstream signaling molecule SHP-2 (green). Right side: a tumor cell with PD-L1 ligand (orange) on its surface. Center: PD-1 binding to PD-L1 with arrows showing inhibition signal flow. Below: alternate panel showing anti-PD-1 antibody (e.g., pembrolizumab) blocking the interaction, restoring T-cell killing function. Labeled annotations in clean sans-serif font, scale arrows, small molecular structure inset. Educational textbook clarity.
| Model | Unknown |
|---|---|
| Language | English |
| Source | gpt-image2.art |
| Creator | gpt-image2.art |
| Collected | August 8, 2026 |
Try the prompts using this demo:
High-quality scientific schematic diagram in Science/Nature journal style. Topic: PD-1/PD-L1 immune checkpoint pathway in the tumor microenvironment. Light gray-white background. Left side: a simplified T-cell cross-section, cell membrane drawn as a phospholipid bilayer (light blue), with PD-1 receptor protein (purple) protruding from the membrane; PD-1 intracellular tail connects via ITSM motif to downstream signaling molecule SHP-2 (green). Right side: a tumor cell with PD-L1 ligand (orange) on its surface. Center: PD-1 binding to PD-L1 with arrows showing inhibition signal flow. Below: alternate panel showing anti-PD-1 antibody (e.g., pembrolizumab) blocking the interaction, restoring T-cell killing function. Labeled annotations in clean sans-serif font, scale arrows, small molecular structure inset. Educational textbook clarity.
Related products
-
-
-
Sale!
-
-
-
-
-
Reviews
There are no reviews yet.